Vega Therapeutics Acquired by Incyte | Healthcare M&A Deal

Incyte has acquired Vega Therapeutics, a healthcare services other business in Delaware, for $1.25 billion. Incyte acquisitions add VGA039, a novel investigational monoclonal antibody targeting Protein S, to expand its hematology portfolio into bleeding disorders. Vega Therapeutics develops therapies for von Willebrand disease, aiming to improve hemostasis and support more convenient subcutaneous prophylaxis for patients who currently rely on frequent intravenous infusions. The healthcare M&A is structured as a platform acquisition and strategic acquisition by a strategic buyer, with total potential consideration up to $2.0 billion including up to $750 million in sales milestone payments, subject to customary closing adjustments.